9.6
Measurement of Bioavailability: Pharmacokinetic Methods
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key m…
Pharmacokinetic methods, like plasma drug concentration and urinary excretion studies, assume a drug's pharmacokinetic profile influences its efficacy.
Plasma drug concentration-time studies involve drug assays using collected blood samples. The resulting plasma drug concentration versus time plot highlights the time of peak plasma concentration, the peak plasma drug concentration, and area under the plasma drug concentration-time curve.
A smaller tmax indicates a faster absorption rate, while a higher Cmax suggests an increased peak drug concentration due to greater absorption, a faster absorption rate, or slower elimination. The AUC reflects the drug’s total bioavailability.
Urinary drug excretion studies employ parameters like cumulative drug amount in the urine 
, rate of drug excretion dDu/dt, and total excretion time t∞.
reflects total drug absorption through the cumulative urine drug concentration-time plot. In the dDu/dt-time graph, the excretion rate initially peaks and diminishes as the elimination completes. t∞ marks the drug absorption and excretion span and critically compares the different drug products.
View the full transcript and gain access to JoVE Core videos
Q1: What does tmax tell you about a drug's absorption rate?
tmax represents the time to reach peak plasma concentration and is inversely related to absorption rate. A smaller tmax indicates faster absorption, meaning the drug reaches its maximum concentration in the bloodstream more quickly. This parameter helps assess how rapidly a drug is absorbed from its administration site into systemic circulation.
Q2: How does Cmax relate to drug bioavailability?
Cmax denotes the peak plasma concentration and correlates with the extent of drug absorption. Higher Cmax values suggest more significant drug uptake into the bloodstream. Combined with other pharmacokinetic parameters, Cmax helps evaluate a drug's therapeutic potential and bioavailability profile.
Q3: What does the area under the plasma drug concentration-time curve represent?
The AUC, or area under the plasma drug concentration-time curve, reflects the drug's total bioavailability by providing an integrated measure of the drug present in systemic circulation over time. This parameter represents the cumulative drug exposure and is essential for comparing drug formulations and assessing therapeutic efficacy.
Q4: How do urinary excretion studies complement plasma concentration analysis?
Urinary excretion studies evaluate drug elimination from the body, complementing plasma analysis by measuring cumulative drug amount in urine and excretion rates. These studies use parameters like dDu/dt (excretion rate) and t∞ (total excretion time) to provide a comprehensive assessment of drug performance alongside plasma concentration data.
Q5: What information does the dDu/dt-time graph provide about drug elimination?
The dDu/dt-time graph displays the rate of drug excretion over time. The excretion rate initially peaks and then diminishes as elimination completes, providing visual insight into the drug's elimination kinetics. This pattern helps pharmacologists understand how quickly the body removes the drug through urinary excretion.
Q6: Why is t∞ important for comparing different drug products?
t∞ marks the drug absorption and excretion span, representing the total time from drug administration until complete elimination. This parameter is critical for comparing different drug formulations and products because it reveals how long the drug remains in the body, influencing dosing intervals and therapeutic outcomes.
Q7: How do plasma drug concentration and urinary excretion methods work together in bioavailability assessment?
Plasma drug concentration studies measure drug levels in blood to determine absorption kinetics through tmax, Cmax, and AUC, while urinary excretion studies track elimination through cumulative urine drug concentration and excretion rates. Integrating these approaches provides a comprehensive assessment of drug performance and guides bioavailability enhancement determination and conceptual approaches for optimizing therapeutic efficacy.